Which patient undergoing mitral valve surgery should also have the tricuspid repair?

Size: px
Start display at page:

Download "Which patient undergoing mitral valve surgery should also have the tricuspid repair?"

Transcription

1 doi: /icvts Interactive CardioVascular and Thoracic Surgery 9 (2009) Best evidence topic - Valves Which patient undergoing mitral valve surgery should also have the tricuspid repair? Giacomo Bianchi*, Marco Solinas, Stefano Bevilacqua, Mattia Glauber Department of Adult Cardiac Surgery, Heart Hospital G. Monasterio Foundation, Massa, Italy Received 29 July 2009; received in revised form 20 August 2009; accepted 9 September 2009 Work in Editorial New Ideas Progress Report Protocol Summary A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was Which patient undergoing mitral valve surgery should also have the tricuspid repair? Altogether 390 papers were found using the reported search, of which 17 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. While a general agreement exists for tricuspid valve (TV) repair in cases of severe regurgitation and concomitant multivalvular disease requiring surgical intervention, current guidelines provide more vague indications for patients with less severe tricuspid regurgitation (TR). Since this condition has a lower event-free survival rate and the prognosis after symptoms development is dismal, a lower threshold and a more aggressive strategy for intervention is needed. In rheumatic valve disease, mitral valve involvement and disease spreading to TV may be responsible for further regurgitation. Although patients with pulmonary hypertension (PH) may benefit from mitral valve replacement (MVR) or balloon valvotomy, many studies found that preoperative PH does not predict late TR. However, patients with high pulmonary pressure have a lower occurrence of late TR. Tricuspid annular dilation is probably the most important factor for late TR. Once established, it might be irreversible even after resolution of PH as well as absence of reverse remodelling. It has been proposed to treat TR independently from the grade of regurgitation when 2 the annular dimension is over 21 mmym or G3.5 cm at echo measurement or when the intra-operative tricuspid annulus (TA) diameter is )70 mm. TV repair should be accomplished in patients with preoperative atrial fibrillation (AF), since it may cause late significant TR development and affect the patient s long-term survival. The presence of a trans-tricuspid pacemaker lead is another known factor for late TR development secondary to adhesions and fibrous retraction. TV repair is probably better than replacement in non-severe organic TV disease. Annuloplasty ring repair has better outcome compared with non-ring based repair techniques; the beneficial effect is also independent of the type of mitral valve surgery performed Published by European Association for Cardio-Thoracic Surgery. All rights reserved. Institutional Report ESCVS Article Proposal for Bailout Procedure Negative Results Follow-up Paper Keywords: Left-sided valve surgery; Tricuspid valve repair; Outcome 1. Introduction A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS w1x. 2. Three-part question In wpatients undergoing mitral valve surgery with moderate tricuspid regurgitationx is wtricuspid repairx superior to wmitral surgery alonex to prevent wlate tricuspid valve regurgitationx? 3. Clinical scenario A 65-year-old woman with severe mitral valve regurgitation and atrial fibrillation (AF) is scheduled for intervention; tricuspid annulus is 40 mm with mild tricuspid *Corresponding author. Mobile: q ; q address: gbianchi@ifc.cnr.it (G. Bianchi) Published by European Association for Cardio-Thoracic Surgery regurgitation (TR) and right ventricular (RV) dilation but no increase in pulmonary artery systolic pressure (PASP). Should tricuspid valve (TV) be repaired and what further operative risk and impacts will this have on your patient s early and late outcomes? 4. Search strategy Medline 1950 to August week using OVID interface: wtricuspid regurgitation.mp. OR exp Tricuspid Valve Insufficiencyyx AND wmitral regurgitation.mp. OR exp Mitral Valve Insufficiencyyx AND wmitral valve repair.mp. OR mitral valve replacement.mp. OR tricuspid valve repair.mp OR tricuspid valve replacement.mp. OR exp Thoracic Surgeryy OR valve surgery.mp. OR exp Heart Valve Prosthesisyx 5. Search outcome Three hundred and ninety papers were found using the reported search. From these, seventeen papers were identified that provided the best evidence to answer the question. These are presented in Table 1. State-of-the-art Best Evidence Topic Nomenclature Historical Pages Brief Case Report Communication

2 1010 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Table 1 Best evidence papers Bonow et al., Class I Severe TR in the setting of ACCyAHA VHD surgery for multivalvular Guidelines: (2008), disease should be focused update corrected (level of evidence: c) Class II Tricuspid annuloplasty is reasonable for mild TR in patients undergoing MV surgery when there is pulmonary hypertension or tricuspid annular dilatation Vahanian et al., Class IIa Concomitant TV repair if (2007), Eur TA diameter )40 mm Heart J, ESC guidelines TV repair in patients with symptomatic, isolated TR late after left-sided valve surgery, in absence of left-sided myocardial or RV dysfunction and without severe pulmonary hypertension Turina et al., 170 patients Follow-up Mean 10.6 years (1802 Retrospective study (1999), (between 1975 patient-years) Circulation, and 1989) who Significant TV regurgitation requiring Switzerland, w2x underwent surgery Surgical procedures Double valve surgery 170 surgical repair worsened the prognosis for chronic patients Retrospective combined aortic Advice for TV repair when hemodynamic study (level IIb) and mitral valvular TV surgery 29 patients (17%) significant regurgitation is present disease CABG 7 patients (4%) Ascending aorta surgery 7 patients (4%) Reoperation involving Tricuspid replacement 2 TV patients Tricuspid reconstruction 2 patients Survival rate in patients with TR Predictors of late outcome At 10 years (cumulative survival) With TV reconstruction 57% Without TV reconstruction 68% Age (Ps0.0011) LVEF (Ps0.0008) Additional TV regurgitation (Ps0.007) Nath et al., 5223 patients One-year survival 91.7% with no TR, Retrospective study (2004), J Am Coll undergoing 90.3% with mild TR, Cardiol, USA, w3x echocardiography; 78.9% with moderate TR, Huge cohort of patients four years follow- 63.9% with severe TR Retrospective up; comparison Long follow-up study (level IIb) survival differences TR grade, pulmonary Moderate or greater TR among TR grades artery pressure and increased mortality regardless Unknown NYHA class at follow-up mortality of PASP HR 1.31 for PASP )40 mmhg; HR 1.32 PA No data correlation with MR grade and TR -40 mmhg TR grade, LVEF and mortality Moderate or greater TR increased mortality regardless of EF HR 1.49 EF-50% HR 1.54 EF)50%

3 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Porter et al., 65 patients with Follow-up duration 11.3"8 years (range Retrospective study (1999), J Heart rheumatic heart 1 30 years) Valve Dis, disease who had No data about preoperative TR Israel, w4x undergone MVR Left-sided valve MV stenosis 44 patients (67%) without TV pathology and surgical MV regurgitation 21 patients No data on preoperative RV status Retrospective surgery intervention (33%) study case series Outlines the late development rate of TR (level IIIb) Mitral valve replacement in all when uncorrected at the time of left-sided cases valve surgery Outcomes 44 patients (67%) developed late TR Moderate 16 patients (36.4%) Severe 18 patients (41%) Risk factors Age RR 1.1 female gender 1.8 Matsuyama et al., Between March Mean follow-up 8.2"3.6 years (range Retrospective study (2003), Ann Thor 1988 and years) Surg, Japan, w5x September 2001 of Long overall follow-up but high variability 174 of 274 patients Late deaths 14 late deaths (8%) of time (may underestimate late TR Retrospective undergoing MV development in some early patients) study (level IIb) surgery did not Early postoperative TR (3qy4q or more) in 4 receive concomitant outcome patients (2%) Mitral valve repair as left-side valve TV surgery surgery in 53% of patients Follow-up of TR grade 28 patients developed TR grade 3q or more (16%) 46 patients Progression of TR over time with preopearative TR 2qy4q, TR had progression in Early postoperative TR grade is unreliable 17 patients (37%) for estimation of late TR progression Risk factors for Preoperative 2q TR: OR 3.9 No assessment of right ventricular significant TR (3q (Ps0.004) AF: OR 9.2 (Ps0.03) dysfunction or tricuspid annulus dilatation or more) left atrium size: OR 2.8 (Ps0.03) Strong correlation with AF and atrial size Recommendation for aggressive TR repair in selected cases Matsunaga et al., From January Tricuspid annuloplasty 21 patients had preoperative Retrospective study (2005), Circulation, 1992 to December TR (moderate or greater) USA; Japan, w6x 2001, patients underwent TVRep Relatively small number of patients consecutive (TR-group) 12 patients TR was Retrospective patients with fmr ignored (no-tr group) Long and complete follow-up study (level IIb) underwent CABG and MVRep. 21 TR moderate or greater 4 patients (44%) of TR group 50% of patients after MVRep showed patients (30%) had at follow-up 8 patients (67%) of no-tr group significant TR at follow-up TR before surgery (PsNS) Presence or absence of residual MR do not Progression of TR after Significant TR 25% at 1 year, affect the incidence of follow-up TR MVRep 53% at 1 3 years, 74% over 3 years Revascularization and MVRep do not reduce RV pressure overload and do not Follow-up MR and TR 14 of 21 patients (64%) with prevent late TR significant recurrent MR had also significant TR Incidence of late TR was independent of whether the TR was surgically treated or 20 of 48 patients (42%) with no ignored (44% vs. 67%; PsNS) recurrent MR had significant TR (PsNS) Significant recurrent MR (31%) reinforces the significance of ventricular geometric Follow-up echo data RV systolic pressure in the TR distortion as ongoing remodelling affecting group was higher than the no-tr RV and LV geometries group Best Evidence Topic LV ejection fraction was not different between the groups

4 1012 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Calafiore et al., From January Follow-up duration 68 months (100% complete) Moderate-or-more ftr, if untreated, can (2009), Ann 1988 to March impair both midterm survival and functional Thorac Surg, 2003, 110 patients Mortality Treated vs. untreated TR group status, even if it seems not to affect early Italy, w7x with functional 30 days: 2% vs. 8.5% outcome mitral regurgitation (Ps0.213) long-term (46y104 Retrospective undergoing mitral patients) 16 patients vs. Reversal of TV remodeling cannot be study (level IIb) valve surgery 30 patients expected with MV surgery alone showed moderateor-more functional TR At 12 months follow-up Functional TR progression is not related to TR repaired with (77 patients) functional MVR progression De Vega technique Treated group (42 patients) Surgical technique can then influence the No TR: 50% late results of TR correction TR 1q: 31% TR 2q: 14% TR 3q: 5% Untreated group (35 patients) No TR: 0% TR 1q: 23% TR 2q: 37% TR 3q: 34% TR 4q: 6% MVR progression and influence on ftr recurrenceyprogression Survival MV repair (60 patients) MR 3q: )3 patients (5%) Late ftr group vs. non late ftr 2y47 (4.3%) vs. 1y13 (7.7%) Ps years treated vs. untreated TR 45.0"6.1% vs. 74.5"5.1% (Ps0.044) Risk factors of Lower mid-term survival (HR 2.7) untreated moderate-or-more TR Survival in NYHA class II or II (HR 1.9) Boyaci et al., Sixty-eight (68) TR grade, LVEF and Moderate or greater Retrospective study (2007), patients undergone mortality TR increased mortality Angiology, MVR without regardless of EF Improvement of functional capacity Turkey, w8x TV surgery HR 1.49 EF-50% in 86% of patients with mild HR 1.54 EF)50% preop TR vs. 54% of those with Retrospective significant TR study (level IIb) Preoperative TR Mild TR (group I) 42 patients (62%) Right ventricular pressure fell and remained lower in patients with mild TR, but not in Significant TR (group II) 26 patients with moderate to severe TR patients (38%) Transmitral F-U Group I vs. Group II (mmhg) gradient 5.2"2.5 vs. 5.6"3.0 (PsNS) Right ventricular Group I (mmhg) 47"1.0 to systolic pressure 31"10 trend prepostoperative Group II 45"9 to42"12 Pulmonary Group I vs. Group II (mmhg) hypertension at F-U 31"10 vs. 42"12 (P-0.05) NYHA Class at F-U Group I vs. Group II NYHA I 19% vs. 2% (P-0.05) NYHA II 67% vs. 46% (P-0.05)

5 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) NYHA III 14% vs. 38% (P-0.05) Hospitalizationyyear Group I vs. Group II 1.1"0.4 vs. 1.8"0.7 (P-0.05) Song et al., Between 1995 and Follow-up Clinical 101"24 months (range Retrospective study (2009), 2000, 638 patients months) Heart, (356 men) with Extensive number of patients Korea, w9x mild (Fgrade 2y4) Echocardiographical TR underwent 64"30 months (range Outlines the natural history of late TR Retrospective surgery without months) development study any procedure on (level IIb) the TV Left-side valve surgery Mitral valve surgery Rheumatic aetiology is strongly associated 323 patients with development of late significant TR Aortic valve surgery 221 patients Female gender has higher incidence probably due to higher prevalence of Double-valve surgery rheumatic disease in this population 94 patients AF is the most striking risk factor for Significant late TR Mitral valve surgery 9.6% development of late significant TR development (31y323 patients) PH is not associated with TR progression Aortic valve surgery 3.2% (7y221 patients) Right ventricular distortion or annular dilatation is associated with late TR Double-valve surgery 11.7% development (11y94 patients) Impact of rheumatic Rheumatic MR 15% (10y65 disease on late TR patients) Non-rheumatic MR 5% (7y133 patients) (Ps0.017) AF 239 patients (37%) before surgery 184 patients persistent AF TV annular dilatation Late TR risk factors Mortality Event-free survival 18 patients (5%) developed AF at follow-up TV annulus increased in both group Late TR 32"6 to40"7 mm Non late TR 40"7 mm P Age (HR 1.0; Ps0.005) Female gender (HR 5.0; Ps0.001) rheumatic aetiology (HR 3.8; Ps0.011) AF (HR 2.6; Ps0.035) peak pressure gradient of TR (HR 1.1; ) Significant TR vs. non late TR 4.9% vs. 16.3% (Ps0.004) Late TR vs. non-late TR 76"6% vs. 91"1% (P-0.001) Best Evidence Topic

6 1014 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Colombo et al., From January Follow-up 25"15.9 months (range 3 49 Prospective study (2001), Cardiovasc 1995 to December months) Surg, Italy, w10x 1998, 50 patients Absence or mild to moderate TR in 83.9% with rheumatic Surgical procedure MVR with mechanical valve: of patients who underwent tricuspid Prospective mitral valve 47 patients procedure single center disease and cohort study functional MVR with bioprosthesis: Undersizing of TV annulus has been (level IIb) TR underwent 3 patients effective even with the De Vega procedure surgery for TVRep with De Vega procedure: MVR and TV 33 patients repair Outcome TVRep group with 3q or 4q TV repair TR Grade 0 or 1q: 19 patients performed if (73%) Grade 1q or 2q: indexed TV 3 patients (11.5%) Grade 2q annular dimension or 3q: 1pt(3.8%) Grade 3q to )21 mmym 2 4q: 3 patients (11.5%) Two patients of five with TV 2 annulus )21 mmym who did not undergo TV annuloplasty had significant TR at follow-up Dreyfus et al., Between 1989 and Mortality No significant difference Retrospective study; consecutive patients (2005), Ann 2001, 311 patients (group 1s1.8%; group 2s0.7%) Thorac Surg, underwent mitral 10 years follow-up patients UK, w11x valve repair Actuarial survival rate Group 1s97.3%, 96.2%, and (MVR). Tricuspid 85.5%; group 2s98.5%, Precise and reproducible method of TV Retrospective annuloplasty 98.5%, and 90.3% at 3, 5, and sizing is used study (level IIb) performed if 10 years, respectively tricuspid annular Demonstrates little or no correlation diameter G70 mm NYHA class Improved in group MVRqTV between tricuspid dilatation and regardless of the annuloplasty (group regurgitation grade of 1s1.59"0.84; group regurgitation. 2s1.11"0.31; Tricuspid dilatation is more reliable than Group 1 MVR P-0.001) TR when assessing secondary TV disease alone (163 patients; 54.4%); TR grade Increased )2 grades in Group 2 MVR 48% of group 1 (MVR alone) plus tricuspid and only 2% in group 2 (MVRq annuloplasty (148 TV annuloplasty) patients; 47.6%) McCarthy et al., From 1990 to Follow-up 8 years (3302 patient-years) Retrospective study no consistent, (2004), J Thorac 1999, 790 patients accurate data for right ventricular function, Cardiovasc Surg, underwent Left-sided valve MVR 425 patients (54%) size and geometry, TV annular size, PAPs USA, w12x TV annuloplasty surgery and other for functional procedures MVRep 276 patients (35%) No analysis of residual MR Cohort study regurgitation using (level IIb) 4 techniques: AVR 199 patients (25%) No analytical correlation between TR and 1. Carpentier survival or progression of NYHA class Edwards semi-rigid AVRep 15 patients (2%) ring Residual TR in 14% of patients early after 2. Cosgrove CABG 205 patients (265) operation Edwards flexible band Distribution of patients Carpentier: 139 patients Late worsening (beyond 6 months) 3. De Vega according to TV repair (17%) associated with patient disease factors procedure technique AND with avoidable causes such as trans- 4. Peri-Guard Cosgrove: 291 patients (37%) tricuspid pacing leads and type of annuloplasty annuloplasty De Vega: 116 patients (15%) 2 non-ring annuloplasties, De Vega and Peri-Guard: 243 patients (31%) Peri-Guard, worsening of TR. Reoperation rate Freedom from reoperation 1 month: 99% 8 years: 97%

7 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Progression to grade Carpentier 3q: 10% - 10% - 3q or 4q TR according 11% - 11% 4q: 5.2% - 5.5% - to TV repair technique 6% - 6% (Ps0.7) 1 month Cosgrove 3q: 10% - 12% - 1 year 12% - NA 4q: 5.3% - 6% - 6% - NA 5 years (Ps0.05) 8 years De Vega 3q: 9% - 12% - 17% - 20% 4q: 4.6-6% - 11% - 13% (Ps0.002) Peri-Guard 3q: 10% - 13% - 19% - 22% 4q: 5.4% - 7% - 13% - 15% (Ps0.0009) Pacemaker lead influence on 3q and 4q TR prevalence Preop TR influence of late TR development (Prevalence of 3q or 4q) 1. grades 0 vs. 1q 2. 2q vs. 3q 3. vs. 4q Risk factors for late TR worsening Preop PMK Lead vs. No PMK Lead 16% - 42% vs. 15% - 23% (1 month 5 years) 9% - 14% - 22% at 1 month 18% - 23% - 29% at 5 years LV dysfunction (Ps0.0002) One-system disease (Ps0.007) AF (Ps0.01) PMK lead (Ps0.04) Tang et al., Between 1978 and Follow-up duration 5.9"4.9 years (range Majority of patients undergoing TV repair (2006), Circulation, 2003, 702 patients 0 21 years) have secondary ( functional ) regurgitation Canada, w13x underwent TV repair in the setting TR repair De Vega procedure 493 Uncorrected moderate and severe TR may Retrospective of concomitant patients persist or even worsen after mitral valve study (level IIb) left-sided valve surgery surgery and Ring annuloplasty 209 patients: revascularization Carpentier n. 114 (54%) Annuloplasty ring refers significant Duran n. 52 (25%) improvement over De Vega repair in long- Cosgrove n. 43 (21%) term survival and event-free survival, as well as recurrence of TR Functional class Ring vs. non ring TV repair NYHA III IV 20% vs. 25% Beneficial effects of a TV annuloplasty ring were independent of the type of Late TR Ring group No TR 15% mitral valve surgery performed Trivial-to-mild TR 55% Moderate-to-severe TR 30% Non-ring group No TR 10% Trivial-to-mild TR 54% Moderate-to-severe TR 36% Recurrence of TR was not significantly associated with the recurrence of MR Best Evidence Topic Outcomes No ring vs. ring (15 years) Freedom from TR 39"11% vs. 82"5% (Ps0.003) Long-term survival 36"8% vs. 49"5% (Ps0.007) Event-free survival 17"6% vs. 34"5%

8 1016 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Predictors Annuloplasty ring Long-term survival (HR 0.7; Ps0.03) Event-free survival (HR 0.8; Ps0.04) Kim et al., From January Distribution of patients Carpentier: 139 patients (17%) Retrospective study (2005), 1994 to December according to TV repair Circulation, 1997, 170 patients technique Cosgrove: 291 patients (37%) Long follow-up Korea, w14x underwent leftside valve surgery De Vega: 116 patients (15%) Tricuspid repair techniques used are also Retrospective and MAZE (Cox known to be burden by high late TR study III) operation for Peri-Guard: 243 patients (31%) recurrence (level IIb) AF Group I 44 patients in sinus Reoperation rate Freedom from reoperation AF affects the worsening of TR over time rhythm; Group II 1 month: 99% 48 patients in AF 8 years: 97% MAZE can prevent this course with MAZE and Group III 78 Preoperative TR grade Group I 12 patients (27.3%) Recovery and maintenance of atrial patients without Group II 8 patients (16.7%) mechanical activity are of great value for MAZE Group III 26 patients (33.3%) such a benefit Progression of TR at follow-up Immediate results (significant TR) Group I 3 patients (6.8%) Group II 1 pt (2.1%) Group III 11 patients (14.1%) PsNS among groups Post-op results (significant TR) Group I 3y41 patients (7.3%) Group II 6y47 pt (12.8%) Group III 26y67 patients (38.8%) Ps0.001 Group I vs. Group III Ps0.005 Group II vs. Group III Atrial contractility contribution and analysis Group II (qmaze) 38 patients of Group II maintained sinus rhythm (Group IIa) 10 patients with no LA mechanical activity (AF, accelerated junctional rhythm, sinus rhythm) Group IIa had smaller LA size preoperatively and lower TR grade at the final follow-up than those in Group IIb (Ps0.038; Ps0.025) Left-side valve surgery MVRyMVRep 174 patients (51.9%) AV surgery alone 74 patients (22.1%) Combined MVqAV surgery 87 patients (4.5%) MVRyMVRep 174 patients (51.9%) AV surgery alone 74 patients (22.1%) Combined MVqAV surgery 87 patients (4.5%)

9 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) TV surgery and Annuloplasty 15 patients (4.5%) technique TR development Significant: 90 patients (26.9%) Severe in 25 patients (7.5%) TR population and risk Age (47.6"13.4 vs. 44.3"13.2 factors (TRq vs. TR-) years, Ps0.04) Event-free survival TR- group at 100, 140, 160 and 97.0"1.1% 175 months 87.7"2.8% 85.9"2.6% 85.9"2.6% Preop AF (83.3 vs. 46.5%, P-0.001) LA dimension (56.9"13.2 vs "11.5 mm, Ps0.006) Prior valve surgery (40.0 vs. 25.3%, Ps0.01). TRq group 94.4"2.4% 86.2"3.7% 70.9"5.9% 62.0"9.8% Ps0.03 Jonjev et al., From July 1994 Follow-up duration Mean 42 months (range In end-stage heart disease and selected (2007), J Card to July 2004, months) patient population the RADO procedure is Surg, Serbia and 226 of 294 effective Montenegro, w16x patients who Functional status Preopertative NYHA class III underwent surgical 70 patients (39.88%) Concomitant reduction of mitral and Prospective intervention for NYHA class IV 126 patients tricuspid insufficiency provides early and study (level IIb) chronic ischemic (69.02%) mean NYHA class long-term beneficial effect, according with mitral 3.9 the natural history of the disease regurgitation had reductive Surgical procedure Mitral valve surgery No data are provided about the long-term annuloplasty of efficacy of De Vega annuloplasty for the double orifices Carpentier mitral ring prevention of late TR development (RADO) 37 patients (16.38%) Semicircular posterior annuloplasty 189 patients (69.02%) TV surgery Best Evidence Topic De Vega annuloplasty 226 patients (100%) Follow-up RADO results Mean NYHA class 1.9 mean EF preoperative 25% to postoperative 34% Mitral valve insufficiency mean grade 3.7"0.4 preoperative to 0.7"0.3 postoperative TV insufficiency mean grade 3.4"0.4 preoperative to 0.9"0.2 prostoperative Survival 5 years 10 years 61.5"4.0% 38.05"8.0%

10 1018 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Freedom from At 10 years 60.0"6.7% decompensation De Bonis et al., Ninety-one DCM Follow-up 1.8"1.2 years (range Retrospective study (2008), Eur J patients (mean age years) Cardiothorac Surg, 61"11.3) No consistent, accurate data were available Italy, w17x submitted to MV Left-sided surgery Edge-to-edgequndersized preoperatively and at follow-up regarding repair ("tricuspid and concomitant annuloplasty 46 patients right atrial dimension, tricuspid annular size Cohort study repair) for procedures (50.5%) undersized and degree of leaflet tethering (level IIb) functional MR annuloplasty 45 patients (49.4%) Small number of patients included CABG 41 patients (45%) uncorrected moderate or less TR in patients AF surgery 14 patients (15.3%) with functional MR often persist and worsen over time TV surgical 13 patients (3qy4q or intervention )TR ) had TV annuloplasty: Annular dilatation and tethering as underlying mechanisms of late TR De Vega Procedure: 7 patients Ring annuloplasty: RV function assessment is essential to 6 patients guide the surgical intervention No TV annuloplasty: 78 patients (with TR-2qy4q) Absence of reverse remodelling influences late TR development Evolution of ftr Absentymild 52 patients (57.1%) Moderate 28 patients (30.7%) Moderately severe 9 patients (9.8%) Severe 2 patients (2.2%) 11 of 91 patients (12%) had progression of TR 14 of the 78 patients (17.9%) no-tr had worsening of TR at least of 2 grades TR evolution mechanisms Predictors of significant late TR Annular dilatation in 75 patients tethering in 6 patients RV dilatation (OR 8.3, Ps0.009) Pre-op. RV dysfunction (OR 13.7, Ps0.0001) TR grade at discharge (OR 5.4, Ps0.01) Pulmonary hypertension Significant ()3q) TR at follow-up: 37% (9y24) among the patients with pulmonary hypertension 3% (2y67) among those with SPAP -40 mmhg at the last echocardiogram (P ) Pattern of LV reverse remodeling group: remodeling Significant TR in only 1 of 49 patients (2%) that demonstrated reverse remodeling

11 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) No reverse remodeling group significant TR in 10 of 42 patients (23.8%) (Ps0.04) fmr, functional mitral regurgitation; MVRep, mitral valve repair; FTR, functional tricuspid regurgitation; TVRep, tricuspid valve repair; PMK, pacemaker; TTE, trans-thoracic echocardiography; TA, tricuspid annulus; MR, mitral regurgitation; AVR, aortic valve replacement; AVRep, aortic valve repair; AV, aortic valve; HR, hazard ratio; OR, odds ratio. 6. Results In 1999, Turina et al. w2x reported that significant tricuspid regurgitation (TR) requiring TV surgery predicts poor survival in patients undergoing valve surgery. Nath et al. w3x found that the survival rate at one year changes significantly in moderate and severe TR groups. Moderate and severe TR increases the mortality regardless of PASP degree and ejection fraction. Porter et al. w4x outlined that among patients who underwent mitral valve replacement (MVR) without TV surgery, 44 (67%) developed late TR (moderate to severe in 34 patients, 77.4%). Matsuyama et al. w5x analyzed the outcome of 174 patients that did not receive TV surgery at the time of intervention. Despite a low percentage in the early postoperative period, 28 patients (16%) developed a TR grade of 3q or more and, out of those with preoperative TR 2qy4q, a progression was observed in 17 patients (37%). Early postoperative TR grade is unreliable for estimation of TR progression. In their series of 124 patients with functional mitral regurgitation (fmr) who underwent CABG and mitral valve repair (MVRep), Matsunaga et al. w6x found no difference in early postoperative TR among corrected-tr and uncorrected-tr groups, but at the last follow-up, 34 patients (49%) had significant TR. The incidence of TR increased from 25% at -1 year to 53% between 1 and 3 years and 74% at )3 years. In the analysis of Calafiore et al. w7x, ftr progression is not related to MVR progression and untreated moderate or more functional TR can impair both mid-term survival and functional status, as outlined by the study of Boyaci et al. w8x. Recently, Song et al. w9x found that TV annulus size tends to increase over time in either corrected or uncorrected TR. Rheumatic aetiology of mitral valve (MV) disease is also associated with development of significant late TR (15% vs. 5%, Ps0.017). In the series of Colombo et al. w10x, 50 patients undergoing mitral valve surgery had their TV corrected if the indexed 2 tricuspid annulus dimension was G21 mmym. At followup, 83.9% of patients who underwent tricuspid procedure had absent or mild and mild-to-moderate TR. In 2005, Dreyfus et al. w11x reported a series of 148 patients where an intra-operative TV annular diameter wtricuspid annulus (TA)x G70 mm was used as criterion for repair, regardless of the preoperative TR grade (equivalent to 4 cm by echocardiography wa. Berrebi, personal communication, November 2006x). TR increased more than two grades in 48% of patients in the no-tv repair group and only in 2% of the MVRqTVRep group. No correlation has been found between preoperative TA dilatation and regurgitation grade. In 2004, McCarthy et al. w12x analyzed 790 patients who had TV repair using two ring (Carpentier Edwards, Edwards flexible band) or two non-ring techniques (De Vega Peri-Guard). Freedom from re-operation was 97% at follow-up. TR severity was stable across time with Carpentier Edwards ring (Ps0.7), increased slowly with Cosgrove Edwards band (Ps0.05), but rose more rapidly with the De Vega (Ps0.002) and Peri-Guard (Ps0.0009) approach. The non-ring annuloplasties showed to be ineffective in preventing late TR development. Presence of pacemaker (PMK) leads were also identified as a risk factor (42% at 5 years). Significant improvement with ring annuloplasty over the De Vega technique in terms of long-term survival, eventfree survival and recurrence of TR has been confirmed by Tang et al. w13x; furthermore, the beneficial effects are independent of the type of the MV surgery performed. Kim et al. w14x outlined that when AF persists after surgery for left-sided valve or when the left atrium mechanical activity is not restored, progression to high grade TR occurs. A recent paper from Kwak et al. w15x reported that 90 patients (26.9%) of 335 with no preoperative TR, undergoing left-sided valve surgery, developed de novo significant TR. Preoperative AF was found to independently contribute to late TR. In the setting of end-stage heart disease, the group of Jonjev et al. w16x outlined that reductive annuloplasty of mitral and TV is an effective procedure with early and long-term beneficial effects on survival, freedom from hospitalization and improvement of functional class. Of 91 patients with dilatative cardiomyopathy submitted to MV repair, De Bonis et al. w17x found that, among those who did not have TR repair, TR worsening of at least 2 grades occurred. Right ventricle dilatation, preoperative RV dysfunction and TR grade at discharge were strong predictors of late significant TR development. Pulmonary hypertension (PH) was also associated with significant TR (grade 3qor more) at follow-up. The absence of reverse remodelling occurred in a significant percentage of patients with late TR (10 patients; 23.8% Ps0.04). Best Evidence Topic

12 1020 G. Bianchi et al. / Interactive CardioVascular and Thoracic Surgery 9 (2009) Clinical bottom line TV insufficiency should be treated during left-sided valve 2 surgery when TR annulus is dilated (G21 mmym ;)70 mm intra-operatively; G3.5 cm at trans-thoracic echocardiography (TTE) w18x) regardless of the absolute grade of regurgitation, in cases of preoperative AF, trans-tricuspid PMK lead and underlying rheumatic disease. Also, ring annuloplasty techniques should be preferred over the nonring techniques. References w1x Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;4: w2x Turina J, Stark T, Seifert B, Turina M. Predictors of the long-term outcome after combined aortic and mitral valve surgery. Circulation 1999;100(19 Suppl):II48 II53. w3x Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;3: w4x Porter A, Shapira Y, Wurzel M, Sulkes J, Vaturi M, Adler Y, Sahar G, Sagie A. Tricuspid regurgitation late after mitral valve replacement: clinical and echocardiographic evaluation. J Heart Valve Dis 1999;1: w5x Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Tokuda Y, Matsuo T. Predictors of residual tricuspid regurgitation after mitral valve surgery. Ann Thorac Surg 2003;6: w6x Matsunaga A, Duran CMG. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation 2005; 112(9 Suppl):I453 I457. w7x Calafiore AM, Gallina S, Iacò AL, Contini M, Bivona A, Gagliardi M, Bosco P, Di Mauro M. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. Ann Thorac Surg 2009;3: w8x Boyaci A, Gokce V, Topaloglu S, Korkmaz S, Goksel S. Outcome of significant functional tricuspid regurgitation late after mitral valve replacement for predominant rheumatic mitral stenosis. Angiology 2007;3: w9x Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, Kang DH, Lee JW, Song JK. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart 2009;11: w10x Colombo T, Russo C, Ciliberto GR, Lanfranconi M, Bruschi G, Agati S, Vitali E. Tricuspid regurgitation secondary to mitral valve disease: tricuspid annulus function as guide to tricuspid valve repair. Cardiovasc Surg 2001;4: w11x Dreyfus GD, Corbi PJ, Chan KMJ, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;1: w12x McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW, Cosgrove DM, Blackstone EH. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg 2004;3: w13x Tang GHL, David TE, Singh SK, Maganti MD, Armstrong S, Borger MA. Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. Circulation 2006;114(1 Suppl):I577 I581. w14x Kim HK, Kim YJ, Kim KI, Jo SH, Kim KB, Ahn H, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS. Impact of the Maze operation combined with left-sided valve surgery on the change in tricuspid regurgitation over time. Circulation 2005;112(9 Suppl):I14 I19. w15x Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, Kim KB, Ahn H, Sohn DW, Oh BH, Park YB. Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with longterm echocardiographic examinations. Am Heart J 2008;115: w16x Jonjev ZS, Mijatov M, Fabri M, Popović S, Radovanović ND. Systematic reductive annuloplasty of the mitral and tricuspid valves in patients with end-stage ischemic dilated cardiomyopathy. J Card Surg 2007 Apr; 2: w17x De Bonis M, Lapenna E, Sorrentino F, La Canna G, Grimaldi A, Maisano F, Torracca L, Alfieri O. Evolution of tricuspid regurgitation after mitral valve repair for functional mitral regurgitation in dilated cardiomyopathy. Eur J Cardiothorac Surg 2008;4: w18x Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol 2009;5: ecomment: Which functional tricuspid regurgitation should be surgically corrected? Authors: Leo A. Bockeria, Bakulev Center for Cardiovascular Surgery, Moscow, Russia; Ivan I. Skopin, Irma M. Tsiskaridze doi: /icvts A We thank Giacomo Bianchi and associates for their actual report w1x. Tricuspid regurgitation (TR) is common in patients with left-sided heart valve disease. It is well known that moderate or more functional TR should be repaired. Many investigators have recommended surgical treatment from moderate to severe TR and assumed that a mild degree of functional TR could be expected to diminish after surgical relief of left-sided valve pathology. But, correction of left-sided valvular disease does not automatically correct TR. Treatment of the mitral lesion alone only decreases the afterload. Neither does it correct tricuspid dilatation nor does it affect preload or right ventricular (RV) function w2x. Dilatation of the tricuspid annulus is progressive and may not be accompanied by TR initially, but eventually leads to it. The normal tricuspid valve (TV) annulus is saddle-shaped. It is known that with functional TR the annulus becomes larger, more planar, and circular. The flattening of the TV annulus that occurs with TR can potentially alter the normal papillary muscle-to-leaflet and annulus relationship. With flattening of the annulus, the low points of the annulus may be stretched away from the papillary muscles, thereby increasing tethering. The tricuspid annulus is a component of both the TV and the right ventricle w2x. Ton-Nu et al. w3x suggest that it is not the RV pressure load or left-sided heart disease that influences the annular remodeling changes observed with functional TR. It is the RV dysfunction and dilation that affect those annular remodeling changes. As suggested by Ton-Nu et al. w3x the RV dysfunction and TR are indeed linked, perhaps through the mechanism of annular shape. Possibly, the tricuspid annulus can be thought of as the gear that modulates the effects of the RV remodeling on TV function. Dreyfus et al. w2x demonstrated that the decision to perform tricuspid annuloplasty based on tricuspid annular dilation rather than on the degree of TR at the time of surgery resulted in improved long-term outcome. In our opinion, as the tricuspid annular dilatation seems to be the underlying mechanism regarding non-organic TR, it may be a more reliable indicator for TV pathology compared with TR w2x. We agree with the authors of this report w1x that TV insufficiency should be treated during left-sided valve surgery when the tricuspid annulus is dilated, regardless of the absolute grade of regurgitation. References w1x Bianchi G, Solinas M, Bevilacqua S, Glauber M. Which patient undergoing mitral valve surgery should also have the tricuspid repair? Interact CardioVasc Thorac Surg 2009;9: w2x Dreyfus GD, Corbi PJ, Chan KMJ, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;79: w3x Ton-Nu TT, Levine RA, Handschumacher MD, Dorer DJ, Yosefy C, Fan D, Hua L, Jiang L, Hung J. Geometric determinants of functional tricuspid regurgitation: insights from 3-dimensional echocardiography. Circulation 2006;114:

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated? Ann Thorac Cardiovasc Surg 2013; 19: 428 434 Online January 31, 2013 doi: 10.5761/atcs.oa.12.01929 Original Article Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should

More information

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Late secondary TR after left sided heart disease correction: is it predictibale and preventable Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary

More information

Management of Tricuspid Regurgitation

Management of Tricuspid Regurgitation Management of Tricuspid Regurgitation Antonis A. Pitsis, FETCS, FESC Thessaloniki Heart Institute, St. Luke s Hospital, Thessaloniki, GREECE HEART FAILURE 2012 BELGRADE SERBIA Does Tricuspid Regurgitation

More information

Development of tricuspid regurgitation late after left-sided valve surgery: A single-center experience with long-term echocardiographic examinations

Development of tricuspid regurgitation late after left-sided valve surgery: A single-center experience with long-term echocardiographic examinations Imaging and Diagnostic Testing Development of tricuspid regurgitation late after left-sided valve surgery: A single-center experience with long-term echocardiographic examinations Jae-Jin Kwak, MD, a Yong-Jin

More information

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction

More information

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility

More information

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for

More information

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun Clinical Outcome of Tricuspid Regurgitation David Messika-Zeitoun I have financial relationships to disclose Consultant for: Edwards, Symetis and Valtech Tricuspid Regurgitation is a Common Finding Tricuspid

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20135 holds various files of this Leiden University dissertation. Author: Braun, Jerry Title: Surgical treatment of functional mitral regurgitation Issue

More information

The Tricuspid Valve: The Not So Forgotten Valve. Manuel J Antunes Cardiothoracic Surgery Coimbra, Portugal

The Tricuspid Valve: The Not So Forgotten Valve. Manuel J Antunes Cardiothoracic Surgery Coimbra, Portugal The Tricuspid Valve: The Not So Forgotten Valve Manuel J Antunes Cardiothoracic Surgery Coimbra, Portugal No Conflicts of Interest to declare with regards to this subject 2 INCIDENCE OF TRICUSPID REGURGITATION

More information

Concomitant Tricuspid Valve Repair :

Concomitant Tricuspid Valve Repair : Concomitant Tricuspid Valve Repair : When to perform while awaiting data?! Steven F Bolling, MD Professor of Cardiac Surgery University of Michigan Is FTR important? Decreased CO Fatigue, decreased exercise

More information

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?

More information

Evolving Indications for Tricuspid Valve Surgery

Evolving Indications for Tricuspid Valve Surgery Current Treatment Options in Cardiovascular Medicine (2010) 12:587 597 DOI 10.1007/s11936-010-0098-1 Valvular, Myocardial, Pericardial, and Cardiopulmonary Diseases Evolving Indications for Tricuspid Valve

More information

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? Prof. Patrizio LANCELLOTTI, MD, PhD GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liège, CHU

More information

Valvular Guidelines: The Past, the Present, the Future

Valvular Guidelines: The Past, the Present, the Future Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,

More information

I have financial relationships to disclose Honoraria from: Edwards

I have financial relationships to disclose Honoraria from: Edwards I have financial relationships to disclose Honoraria from: Edwards Mitral Valve Annuloplasty in Ischemic Mitral regurgitation Jean François Avierinos Hôpital Timone Marseille August 28, 2012 Ischemic MR

More information

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Steven F Bolling Professor of Cardiac Surgery University of Michigan Optimal Treatment of Functional MR Steven F Bolling Professor of Cardiac Surgery University of Michigan Functional MR Functional MR in Ischemia Badhwar, Bolling, chapter in: Advances in Heart Failure,

More information

Haiping Wang 1,2, Xiancheng Liu 2, Xin Wang 2, Zhenqian Lv 2, Xiaojun Liu 2, Ping Xu 1. Introduction

Haiping Wang 1,2, Xiancheng Liu 2, Xin Wang 2, Zhenqian Lv 2, Xiaojun Liu 2, Ping Xu 1. Introduction Original Article Comparison of outcomes of tricuspid annuloplasty with 3D-rigid versus flexible prosthetic ring for functional tricuspid regurgitation secondary to rheumatic mitral valve disease Haiping

More information

MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT)

MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT) UNIVERSITY OF PADUA, SCHOOL OF MEDICINE Department of Cardiac,Thoracic and Vascular Sciences Padua, Italy MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT) Luigi P. Badano**, MD, PhD, FESC,

More information

3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD

3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD 3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD Asan Medical Center University of Ulsan College of Medicine Seoul, Korea Causes of TR Primary causes (25%) Rheumatic Myxomatous

More information

Surgical treatment of tricuspid regurgitation after mitral valve surgery: a retrospective study in China

Surgical treatment of tricuspid regurgitation after mitral valve surgery: a retrospective study in China RESEARCH ARTICLE Open Access Surgical treatment of tricuspid regurgitation after mitral valve surgery: a retrospective study in China Zong-Xiao Li 1, Zhi-Peng Guo 1, Xiao-Cheng Liu 1, Xiang-Rong Kong 1,2,

More information

Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery

Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery John M. Stulak, MD,* Hartzell V. Schaff, MD, Joseph A. Dearani, MD, Thomas A. Orszulak,

More information

Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery

Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery Featured Article Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery Bettina Pfannmüller, Piroze Davierwala, Gregor Hirnle, Michael A. Borger, Martin Misfeld, Jens

More information

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board

More information

Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Disclosures Ownership Interest: Millipede and Pipeline TR is BAD Decreased

More information

The Edge-to-Edge Technique f For Barlow's Disease

The Edge-to-Edge Technique f For Barlow's Disease The Edge-to-Edge Technique f For Barlow's Disease Ottavio Alfieri, Michele De Bonis, Elisabetta Lapenna, Francesco Maisano, Lucia Torracca, Giovanni La Canna. Department of Cardiac Surgery, San Raffaele

More information

Risk Analysis of the Long-Term Outcomes of the Surgical Closure of Secundum Atrial Septal Defects

Risk Analysis of the Long-Term Outcomes of the Surgical Closure of Secundum Atrial Septal Defects Korean J Thorac Cardiovasc Surg 2017;50:78-85 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) CLINICAL RESEARCH https://doi.org/10.5090/kjtcs.2017.50.2.78 Risk Analysis of the Long-Term Outcomes of the

More information

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,

More information

Understanding the guidelines for Interventions in MR. Ali AlMasood

Understanding the guidelines for Interventions in MR. Ali AlMasood Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe

More information

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles

More information

Concomitant mitral valve replacement and tricuspid valvuloplasty for severe mitral stenosis

Concomitant mitral valve replacement and tricuspid valvuloplasty for severe mitral stenosis European Review for Medical and Pharmacological Sciences 2017; 21: 3436-3440 Concomitant mitral valve replacement and tricuspid valvuloplasty for severe mitral stenosis X.-D. HOU, F. DING, X.-K. WANG,

More information

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Dr Χρήστος ΑΛΕΞΙΟΥ MD, PhD, FRCS(Glasgow), FRCS(CTh), CCST(UK) Consultant Cardiothoracic Surgeon Normal Mitral Valve Function Mitral Regurgitation

More information

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular

More information

Tricuspid leaflet repair: innovative solutions

Tricuspid leaflet repair: innovative solutions Perspective Tricuspid leaflet repair: innovative solutions Jack H. Boyd 1, J. James B. Edelman 2, David H. Scoville 1, Y. Joseph Woo 1 1 Department of Cardiothoracic Surgery, Stanford University School

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Mohammad Sharif Popal, Jin-Tao Fu, Qiu-Ming Hu, Tian-Ge Luo, Shuai Zheng, Xu Meng

Mohammad Sharif Popal, Jin-Tao Fu, Qiu-Ming Hu, Tian-Ge Luo, Shuai Zheng, Xu Meng Original Article Intraoperative method based on tricuspid annular circumference in patients with mild or no tricuspid regurgitation during left-sided cardiac valve surgery for the prophylactic tricuspid

More information

Long-term results (22 years) of the Ross Operation a single institutional experience

Long-term results (22 years) of the Ross Operation a single institutional experience Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department

More information

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Severe left ventricular dysfunction and valvular heart disease: should we operate? Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict

More information

Persistent Tricuspid Regurgitation After Tricuspid Annuloplasty During Redo Valve Surgery Affects Late Survival and Valve-Related Events

Persistent Tricuspid Regurgitation After Tricuspid Annuloplasty During Redo Valve Surgery Affects Late Survival and Valve-Related Events Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage Persistent Tricuspid Regurgitation After Tricuspid Annuloplasty During Redo

More information

Quality Outcomes Mitral Valve Repair

Quality Outcomes Mitral Valve Repair Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding

More information

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral

More information

Basic principles of Rheumatic mitral valve Repair

Basic principles of Rheumatic mitral valve Repair Basic principles of Rheumatic mitral valve Repair Prof. Gebrine El Khoury, MD DEPARTMENT OF CARDIOVASCULAR AND THORACIC SURGERY ST. LUC HOSPITAL - BRUSSELS, BELGIUM 1 Rheumatic MV disease MV repair confers

More information

Three-Dimensional P3 Tethering Angle at the Heart of Future Surgical Decision Making in Ischemic Mitral Regurgitation

Three-Dimensional P3 Tethering Angle at the Heart of Future Surgical Decision Making in Ischemic Mitral Regurgitation Accepted Manuscript Three-Dimensional P3 Tethering Angle at the Heart of Future Surgical Decision Making in Ischemic Mitral Regurgitation Wobbe Bouma, MD PhD, Robert C. Gorman, MD PII: S0022-5223(18)32805-8

More information

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve

More information

Asymptomatic Valvular Disease:

Asymptomatic Valvular Disease: Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown

More information

Imaging to select patients for Transcatheter TV

Imaging to select patients for Transcatheter TV Imaging to select patients for Transcatheter TV Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands San Diego, february 2018 Research grants: Medtronic, Biotronik, Boston Scientific,

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical

More information

Atrioventricular valve repair: The limits of operability

Atrioventricular valve repair: The limits of operability Atrioventricular valve repair: The limits of operability Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart

More information

Late Outcome of Tricuspid Annuloplasty Using a Flexible Band/Ring for Functional Tricuspid Regurgitation

Late Outcome of Tricuspid Annuloplasty Using a Flexible Band/Ring for Functional Tricuspid Regurgitation Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Late Outcome of Tricuspid Annuloplasty Using a Flexible Band/Ring

More information

Mitral Valve Repair for Functional Mitral Regurgitation in End-Stage Dilated Cardiomyopathy Role of the Edge-to-Edge Technique

Mitral Valve Repair for Functional Mitral Regurgitation in End-Stage Dilated Cardiomyopathy Role of the Edge-to-Edge Technique Mitral Valve Repair for Functional Mitral Regurgitation in End-Stage Dilated Cardiomyopathy Role of the Edge-to-Edge Technique Michele De Bonis, MD; Elisabetta Lapenna, MD; Giovanni La Canna, MD; Eleonora

More information

Chronic Primary Mitral Regurgitation

Chronic Primary Mitral Regurgitation Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......

More information

Index. B B-type natriuretic peptide (BNP), 76

Index. B B-type natriuretic peptide (BNP), 76 Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible

More information

Mitral Valve Repair for Functional Mitral Regurgitation- Description of A New Technique and Classification System

Mitral Valve Repair for Functional Mitral Regurgitation- Description of A New Technique and Classification System Case Report Mitral Valve Repair for Functional Mitral Regurgitation- Description of A New Technique and Classification System Antonio Chiricolo 1*, Leonard Y Lee 2 1 Department of Anesthesiology, Rutgers

More information

Proposal of a Novel Index for Selection of Optimal Annuloplasty Ring Size for Tricuspid Annuloplication

Proposal of a Novel Index for Selection of Optimal Annuloplasty Ring Size for Tricuspid Annuloplication Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Proposal of a Novel Index for Selection of Optimal Annuloplasty

More information

Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation

Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation Matthew L. Williams, MD, Mani A. Daneshmand, MD, James G. Jollis, MD, John

More information

What is the Role of Surgical Repair in 2012

What is the Role of Surgical Repair in 2012 What is the Role of Surgical Repair in 2012 The Long-Term Results of Surgery Raphael Rosenhek Department of Cardiology Medical University of Vienna European Society of Cardiology 2012 Munich, August 27th

More information

The Ross Procedure: Outcomes at 20 Years

The Ross Procedure: Outcomes at 20 Years The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:

More information

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION ESC CONGRESS HIGHLIGHTS VALVULAR HEART DISEASE AND PULMONARY CIRCULATION N. Ajmone Marsan (Leiden, NL) MD, PhD, FESC Conflicts of Interest None CONTENTS Pulmonary arterial hypertension Rheumatic heart

More information

42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim

42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim 42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of

More information

Clinical material and methods. Fukui Cardiovascular Center, Fukui, Japan

Clinical material and methods. Fukui Cardiovascular Center, Fukui, Japan Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui

More information

Tricuspid Annuloplasty Using the MC 3 Ring for Functional Tricuspid Regurgitation

Tricuspid Annuloplasty Using the MC 3 Ring for Functional Tricuspid Regurgitation Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Tricuspid Annuloplasty Using the MC 3 Ring for Functional Tricuspid

More information

Surgical repair techniques for IMR: future percutaneous options?

Surgical repair techniques for IMR: future percutaneous options? Surgical repair techniques for IMR: can this teach us about future percutaneous options? Genk - Belgium Prof. Dr. R. Dion KULeu Disclosure slide Robert A. Dion I disclose the following financial relationships:

More information

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,

More information

De Vega Annuloplasty for Functional Tricupsid Regurgitation: Concept of Tricuspid Valve Orifice Index to Optimize Tricuspid Valve Annular Reduction

De Vega Annuloplasty for Functional Tricupsid Regurgitation: Concept of Tricuspid Valve Orifice Index to Optimize Tricuspid Valve Annular Reduction ORIGINAL ARTICLE Cardiovascular Disorders http://dx.doi.org/10.3346/jkms.2013.28.12.1756 J Korean Med Sci 2013; 28: 1756-1761 De Vega Annuloplasty for Functional Tricupsid Regurgitation: Concept of Tricuspid

More information

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi SC Cardiochirurgia U Universita degli Studi di Torino PORT-ACCESS TECNIQUE Reduce surgical trauma Minimize disruption of the chest wall

More information

Assessing the Impact on the Right Ventricle

Assessing the Impact on the Right Ventricle Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal

More information

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,

More information

Tricuspid valve surgery in patients with a systemic right ventricle

Tricuspid valve surgery in patients with a systemic right ventricle Tricuspid valve surgery in patients with a systemic right ventricle Roderick Scherptong, Hubert Vliegen, Michiel Winter, Barbara Mulder, Ernst van der Wall, Dave Koolbergen, Mark Hazekamp Eduard Holman,

More information

Management of Difficult Aortic Root, Old and New solutions

Management of Difficult Aortic Root, Old and New solutions Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult

More information

Valve Analysis and Pathoanatomy: THE MITRAL VALVE

Valve Analysis and Pathoanatomy: THE MITRAL VALVE : THE MITRAL VALVE Marc R. Moon, M.D. John M. Shoenberg Chair in CV Disease Chief, Cardiac Surgery Washington University School of Medicine, St. Louis, MO Secretary, American Association for Thoracic Surgery

More information

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

The Key Questions in Mitral Valve Interventions. Where Are We in 2018? The Key Questions in Mitral Valve Interventions Where Are We in 2018? Gilles D. DREYFUS, MD, FRCS, FESC Professor of Cardiothoracic Surgery 30 GIORNATE CARDIOLOGICHE TORINESI - OCT 2018 Are guidelines

More information

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology Aortic Stenosis: UPDATE 2010 Anjan Sinha, MD Krannert Institute of Cardiology None Disclosures 67-Year-Old Male Dyspnea and angina Class III heart failure No PND or orthopnea 3/6 late peak SEM Diminished

More information

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the

More information

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data

More information

Changes in Right Ventricular Volume and Function After Tricuspid Valve Surgery

Changes in Right Ventricular Volume and Function After Tricuspid Valve Surgery 1142 CHOI JW et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Cardiovascular Surgery Changes in Right Ventricular Volume and Function

More information

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines Christophe Tribouilloy Amiens, France I have no financial relationships to disclose related

More information

Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation

Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation Featured Article Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation Igor Gosev 1, Maroun Yammine 1, Marzia Leacche 1, Siobhan McGurk 1, Vladimir Ivkovic 1, Michael

More information

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Degenerative MR is not Functional MR 2o - Functional MR : Ventricular Problem!!

More information

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material

More information

Surgical repair of massive dilatation of the right atrium with tricuspid regurgitation

Surgical repair of massive dilatation of the right atrium with tricuspid regurgitation Okada et al. Journal of Cardiothoracic Surgery (2018) 13:83 https://doi.org/10.1186/s13019-018-0769-7 CASE REPORT Open Access Surgical repair of massive dilatation of the right atrium with tricuspid regurgitation

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος MV anatomy Otto C. NEJM 2001 Leaflets anatomy 2% of population Etiology Terminology

More information

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens MITRAL REGURGITATION IN PATIENT WITH SEVERE AORTIC VALVE STENOSIS Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens I HAVE NOTHING TO DECLARE Management

More information

Primary Mitral Regurgitation

Primary Mitral Regurgitation EURO VALVE Madrid News from Valves Guidelines 2012: What s new and Why? Primary Mitral Regurgitation Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology Heart Valve Clinic,

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

Outline. EuroScore II. Society of Thoracic Surgeons Score. EuroScore II

Outline. EuroScore II. Society of Thoracic Surgeons Score. EuroScore II SURGICAL RISK IN VALVULAR HEART DISEASE: WHAT 2D AND 3D ECHO CAN TELL YOU AND WHAT THEY CAN'T Ernesto E Salcedo, MD Professor of Medicine University of Colorado School of Medicine Director of Echocardiography

More information

Edwards' solution for patients suffering from tricuspid valve disease

Edwards' solution for patients suffering from tricuspid valve disease Edwards' solution for patients suffering from tricuspid valve disease R. S. von Bardeleben, MD Head Structural and Heart Valve Center Heart Center Cardiology I, University Medicine Mainz Germany Potential

More information

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; Επιµορφωτικά Σεµινάρια Ειδικευοµένων Καρδιολογίας 7 Απριλίου 2012 M Chrissoheris MD FACC THV Department HYGEIA Hospital Degenerative MR (DMR) Usually refers to an anatomic

More information

Spotlight on Valvular Heart Disease Guidelines

Spotlight on Valvular Heart Disease Guidelines Spotlight on Valvular Heart Disease Guidelines Aortic Valve Disease Raphael Rosenhek Department of Cardiology Medical University of Vienna Palermo, April 26 th 2018 1998 2002 2006 2007 2008 2012 2014 2017

More information

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV. Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume

More information

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve

More information

When Does 3D Echo Make A Difference?

When Does 3D Echo Make A Difference? When Does 3D Echo Make A Difference? Wendy Tsang, MD, SM Assistant Professor, University of Toronto Toronto General Hospital, University Health Network 1 Practical Applications of 3D Echocardiography Recommended

More information

APOLLO TMVR Trial Update: Case Presentation

APOLLO TMVR Trial Update: Case Presentation APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure

More information

CLINICAL COMMUNIQUE 16 YEAR RESULTS

CLINICAL COMMUNIQUE 16 YEAR RESULTS CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced

More information

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences

More information

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative

More information

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New

More information

Flexible band versus rigid ring annuloplasty for tricuspid regurgitation: a systematic review and meta-analysis

Flexible band versus rigid ring annuloplasty for tricuspid regurgitation: a systematic review and meta-analysis Systematic Review Flexible band versus rigid ring annuloplasty for tricuspid regurgitation: a systematic review and meta-analysis Nelson Wang, Steven Phan, David H. Tian 2,3, Tristan D. Yan 2, Kevin Phan,2

More information